Articles

Home
- Key Staff
- Client Area
Articles
- Definitions

FDA’s Bioresearch Monitoring (BIMO) Inspections

FDA BIMO inspections, Form 483 and Warning Letter

BIMO, the Bioresearch Monitoring Program, is a Food and Drug Administration (FDA) program of on-site inspections to ensure the quality and integrity of the data submitted to the agency from regulated clinical trials of investigational drugs, devices, and biologics. Inspections are made both in the U.S. and internationally at clinical investigator sites, institutional review boards (IRBs), and sponsors (e.g., pharmaceutical, medical device, and biologic companies, including monitors and contract research organizations or CR0s working under the sponsor).

Nike Sneakers Miesten kengät laajasta valikoimasta

The Historical Rise of Pharmaceutical Regulation

The first rumblings for US drug legislation began after the Civil War, which had spurred the separation of drug manufacturers from drug prescribers and drug dispensers. This was the time of the traveling medicine shows selling dangerous, addictive or just non-sense patent medicines. Today's pharmaceutical companies got their start in the apothecary shops of that time, but still, most drugs were imported from Europe. In fact the U.S was a dumping ground for substandard and contaminated drugs.

Sport media Nike WMNS Air Force 1 Shadow White/Hydrogen Blue-Purple

Subcategories

Page 6 of 11

Default
Title
Date
Random

FDA Form 1572 - Guidance on the FDA's Statement of Investigator Form

In July 2008, FDA released a draft guidance to answer frequent questions about Form FDA-1572, also called the Statement of…
Read More
Clinical Trial Accrual Hampered by Many Factors

In recent years, cancer patients are more knowledgeable and willing to participate in clinical trials, but issues pertaining to physician…
Read More
Clinical Research Regulation: FDA vs. ICH

On May 9th, 1997, the US Food and Drug Administration (FDA) published in the FEDERAL REGISTER (vol. 62, No 90),…
Read More
The Historical Rise of Pharmaceutical Regulation

The first rumblings for US drug legislation began after the Civil War, which had spurred the separation of drug manufacturers…
Read More
Time Management for the Research Professional

It's been said that a pharmaceutical company loses $1 million for every day of delay during clinical research and development.…
Read More
Latin Abbreviations Ad Nauseam

In case your Latin is a little rusty, here's a list of abbreviations commonly used in medical charts and prescriptions.…
Read More
Surviving an FDA Inspection of Your Clinical Trial Site

The Investigational New Drug (IND) regulations went into effect in 1963. Ever since, the U.S. Food and Drug Administration (FDA)…
Read More
Consulting is an Art

...or Why I'm Not a Singing CRA. During those confusing and wondrous years, when a young man ponders his career…
Read More
Illuminating the Diagnosis of Intracranial Hematoma

Without urgent pressure-relieving surgery, the chance of survival drops quickly for head trauma patients having a severe intracerebral hematoma (bleeding…
Read More
FDA’s Bioresearch Monitoring (BIMO) Inspections

BIMO, the Bioresearch Monitoring Program, is a Food and Drug Administration (FDA) program of on-site inspections to ensure the quality…
Read More

load more hold SHIFT key to load all load all